Coya Therapeutics, Inc.
COYADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
COYA Earnings Report
EPS Est: $-0.36 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How COYA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
COYA 302 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Coya Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Coya Therapeutics, Inc.'s (COYA) pipeline across Phase 2. Its lead program is COYA 302 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Coya Therapeutics, Inc.'s next FDA catalyst?→
Coya Therapeutics, Inc.'s (COYA) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COYA biotech catalysts?→
Add COYA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Coya Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.